Erratum to “Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration”

This erratum corrects the following: Molto, C, Hwang TJ, Borrell M, et al. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. Cancer. 2020;126:4390–4399. doi:10.1002/cncr.33095 Consolación Molto’s affiliation was incomplete in the published version of this article. Dr. Molto’s affiliation should read as follows: Consolación Molto, MD, Oncology Department, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomèdica Sant Pau, and Departament de medicina de la Universitat Autònoma de Barcelona, Barcelona, Spain. The authors regret the error.